Department of Anesthesiology, Xi'an Children Hospital, Xi'an 710032, China.
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai 200032, China.
Int J Mol Sci. 2023 Mar 8;24(6):5205. doi: 10.3390/ijms24065205.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Although a cadre of therapeutic strategies have been made available for CVDs in the clinical setting, predominantly through medication and surgery, these do not fully address the clinical needs of patients with CVD. As a new technique for CVD treatment, nanocarriers are employed to modify and package medications to ease the targeting of tissues, cells and molecules within the cardiovascular system. Nanocarriers are made of biomaterials, metals, or a combination of these materials, with sizes similar to bioactive molecules such as proteins and DNA. Cardiovascular nanomedicine (CVN) has only surfaced in recent years and is still in its infancy. Ample studies have displayed promise for the clinical utility of nanomedicine techniques, courtesy of continued perfection in nanocarrier design to optimize drug delivery and treatment outcomes. Here in this review, we will summarize the research advances in the literature on nanoparticles in the management of CVDs, including ischemic and coronary heart disease (e.g., atherosclerosis, angina pectoris and myocardial infarction), myocardial ischemia-reperfusion injury, aortic aneurysm, myocarditis, hypertension, and pulmonary artery hypertension and thrombosis.
心血管疾病 (CVD) 是全球发病率和死亡率的主要原因。尽管临床上已经有一系列治疗 CVD 的策略，主要通过药物和手术，但这些策略并不能完全满足 CVD 患者的临床需求。作为 CVD 治疗的新技术，纳米载体被用于修饰和包装药物，以方便靶向心血管系统内的组织、细胞和分子。纳米载体由生物材料、金属或这些材料的组合制成，其大小与蛋白质和 DNA 等生物活性分子相似。心血管纳米医学 (CVN) 近年来才出现，仍处于起步阶段。大量研究显示，纳米医学技术具有临床应用的前景，这得益于纳米载体设计的不断完善，以优化药物输送和治疗效果。在这篇综述中，我们将总结文献中关于纳米颗粒在 CVD 管理中的研究进展，包括缺血性和冠心病（如动脉粥样硬化、心绞痛和心肌梗死）、心肌缺血再灌注损伤、主动脉瘤、心肌炎、高血压、肺动脉高压和血栓形成。
